Abstract
Focal nodular hyperplasia (FNH) is the second most common benign tumor of the liver. PET/MR imaging can accurately detect FNH by displaying characteristic MR imaging characteristics, especially with hepatocyte-specific contrast agents. FNH tends to show normal to decreased metabolic uptake on PET/MR.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Hussain SM, Terkivatan T, Zondervan PE, Lanjouw E, de Rave S, Ijzermans JN, et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics. 2004;24(1):3–17.
Kurtaran A, Becherer A, Pfeffel F, Müller C, Traub T, Schmaljohann J, et al. 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. Liver. 2000;20(6):487–90.
Purysko AS, Remer EM, Coppa CP, Obuchowski NA, Schneider E, Veniero JC. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol. 2012;198(1):115–23.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Matthews, R. (2018). Focal Nodular Hyperplasia. In: PET/MR Imaging . Springer, Cham. https://doi.org/10.1007/978-3-319-65106-4_69
Download citation
DOI: https://doi.org/10.1007/978-3-319-65106-4_69
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-65105-7
Online ISBN: 978-3-319-65106-4
eBook Packages: MedicineMedicine (R0)